Real-World Data in 2025 and Beyond

Closing the
strategy gap

While the pharma industry at large realizes the value of real-world data, Norstella’s survey of life sciences executives reveals that many manufacturers are missing out on its full potential. Here are our insights on the biggest barriers in maximizing RWD’s value, why it’s time to rethink your approach to the ROI of RWD, and three key pillars to building the ideal RWD strategy—and how to future-proof it.

white paper

Real-world data in 2025 and beyond: Closing the strategy gap

Authors Ilan Behm and Ted Search dive into how to maximize the value of RWD in today’s clinically complex pharmaceutical landscape.

Access the white paper

Article

Pharma’s Real-World Data Dilemma: Strategic Asset or Wasted Resource?

For pharma companies, maximizing RWD’s potential means crafting a better implementation strategy. In this article, Ilan Behm and Ted Search outline three key pillars for building a cohesive RWD plan.

Access the article

infographic

The ROI of real-world data: Understanding the current and future state of RWD

Norstella surveyed 200 life sciences executives about the business impact of real-world data and the biggest barriers in maximizing ROI.

Access the infographic

Our AI capabilities are built to evolve—transforming data into insight, insight into action, and action into impact.

See Norstella AI in action